Because of the observed effects on cardiovascular risk markers in patients with T2D and the demonstration of GLP-1 receptor localization to cardiac and vascular tissues, several investigations have addressed the question of potential direct effects of GLP-1 receptor agonists on the cardiovascular system. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.